Curasight A/S
Jacob Madsen has extensive experience in the medical field, serving as Chief Production Manager at Rigshospitalet since July 1999. Prior to this role, Jacob Madsen gained valuable expertise while completing a Master of Science degree at Aarhus University from September 1992 to June 1999.
This person is not in any teams
Curasight A/S
Curasight is a biotech company focused on addressing the need for improved diagnosis and treatment of several cancer indications. The Company has developed a highly specific PET (Positron emission tomography) imaging ligand, uTRACE®, targeting the receptor uPAR, which is a biomarker only expressed in cancer. uTRACE® will become a game-changer inthe diagnosis and treatment of cancer patients.In addition, with the promising results obtained within diagnostics Curasight will also pursues uPAR targeted radionuclide therapy using the uTREAT® ligand. As PET imaging and radionuclide therapy is based on the same uPAR binding peptide, a uTRACE® scan can precisely predict where subsequent targeted radiation therapy will be delivered. uTRACE® covers the diagnostic path and uTREAT® covers the therapy. This will be the new management and treatment of cancer patients in the future.